ABL001 Pre-FDA Meeting Scheduled for August
"Expanding Partnerships with China to Accelerate Development"

ABL Bio will begin Phase 3 clinical trials of its bispecific antibody immunotherapy, "Zevastomig (ABL111)," in December this year. Based on the data from the completed Phase 1 trials, the company has agreed with the U.S. Food and Drug Administration (FDA) to proceed directly to Phase 3, bypassing Phase 2.


Sanghoon Lee, CEO of ABL Bio, is presenting at the corporate briefing held on the 7th at the Conrad Hotel in Yeouido, Seoul. Photo by Minjae Kwak

Sanghoon Lee, CEO of ABL Bio, is presenting at the corporate briefing held on the 7th at the Conrad Hotel in Yeouido, Seoul. Photo by Minjae Kwak

View original image

At a corporate briefing held in Yeouido on July 7, Sanghoon Lee, CEO of ABL Bio, stated, "We received FDA approval to conduct a fast-track Phase 3 trial with the substance that completed Phase 1." ABL111 is a bispecific antibody immunotherapy co-developed by ABL Bio and U.S.-based NovaBridge Biosciences. It targets both the protein "Claudin 18.2 (CLDN18.2)," which is overexpressed in cancers such as gastric and pancreatic cancer, and the immune T-cell activating receptor "4-1BB," thereby synergistically inducing cancer cell recognition and immune activation. ABL Bio, together with NovaBridge, is developing the drug with the goal of entering the first-line treatment market for gastric cancer.


If the company had proceeded to Phase 3 after completing Phase 2 as originally planned, the timing for obtaining data could have been delayed until 2032. However, with this decision, ABL Bio expects to complete Phase 3 clinical data by the end of 2029 or 2030. The fact that Astellas is already selling "Zolbetuximab" as a first-line therapy in the Claudin 18.2 targeted therapy market is cited as a major reason for accelerating the development timeline.


ABL Bio believes that ABL111 will differentiate itself from existing therapies in terms of safety and the potential to treat a broader patient population. CEO Lee explained that the company has secured data showing superiority over Zolbetuximab with respect to side effects. He highlighted as a key differentiator that the objective response rate (ORR) was 83.3% even among patients with low expression of both Claudin 18.2 and PD-L1 (5 out of 6 patients). The related Phase 1 clinical data will be presented at the European Society for Medical Oncology (ESMO) this year.


Regarding ABL301, which is being co-developed with Sanofi, the company officially dispelled related concerns on this day. CEO Lee stated, "We received documentation from Sanofi confirming that there are no issues with subsequent clinical trials," and emphasized, "This project has not been terminated." He added, "The letter also stated that clinical trials will resume as soon as the biomarker is ready." Earlier this year, Sanofi announced it would reprioritize ABL301's clinical development, which led to a nearly 30% drop in ABL Bio's stock price.


"Tovetumig (ABL001)," which is being developed as a treatment for cholangiocarcinoma, is scheduled for a pre-meeting with the FDA in early August. U.S. partner Compass Therapeutics plans to submit a Biologics License Application (BLA) to the FDA for use as a second-line treatment for cholangiocarcinoma by the end of this year or early next year, following this meeting.



ABL Bio also plans to expand its collaborations with Chinese companies to accelerate antibody discovery and early-stage clinical trials. CEO Lee stated, "China is extremely fast in antibody discovery and early clinical stages," and added, "We've concluded that partnering with China would be the best option." He continued, "Our goal is not to stop at technology transfer, but to become a company that shares commercialization profits with global pharmaceutical companies."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing